Livforsakringsbolaget Skandia Omsesidigt Makes New $196,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Livforsakringsbolaget Skandia Omsesidigt purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 5,300 shares of the biopharmaceutical company’s stock, valued at approximately $196,000.

Other large investors also recently made changes to their positions in the company. Advisory Services Network LLC raised its holdings in Halozyme Therapeutics by 50.5% in the 1st quarter. Advisory Services Network LLC now owns 903 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 303 shares during the period. Belpointe Asset Management LLC boosted its position in Halozyme Therapeutics by 42.0% in the first quarter. Belpointe Asset Management LLC now owns 1,238 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 366 shares in the last quarter. Harbour Investments Inc. acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $51,000. Acadian Asset Management LLC bought a new stake in Halozyme Therapeutics during the 1st quarter worth approximately $92,000. Finally, Point72 Hong Kong Ltd acquired a new stake in Halozyme Therapeutics during the 2nd quarter valued at $156,000. Institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on HALO shares. TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday. TD Cowen assumed coverage on shares of Halozyme Therapeutics in a research note on Thursday, February 29th. They set an “outperform” rating and a $54.00 price target for the company. Finally, Benchmark reaffirmed a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.29.

View Our Latest Analysis on HALO

Halozyme Therapeutics Stock Down 0.6 %

Shares of HALO stock opened at $37.81 on Friday. The company has a market capitalization of $4.80 billion, a price-to-earnings ratio of 17.92, a P/E/G ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 12-month low of $29.85 and a 12-month high of $45.00. The firm has a fifty day moving average of $39.50 and a 200-day moving average of $37.76. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The firm had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 3.45 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at $6,519,075.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 30,000 shares of company stock worth $1,196,800 in the last three months. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Recommended Stories

Want to see what other hedge funds are holding HALO? Visit to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with's FREE daily email newsletter.